Company Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States.
The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy.
The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye.
The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system.
The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016.
Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 19, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Dr. Edward M. Kaye M.D., Ph.D. |
Contact Details
Address: 45 Wiggins Avenue Bedford, Massachusetts 01730 United States | |
| Phone | 781-430-8200 |
| Website | stoketherapeutics.com |
Stock Details
| Ticker Symbol | STOK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001623526 |
| CUSIP Number | 86150R107 |
| ISIN Number | US86150R1077 |
| Employer ID | 47-1144582 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Edward M. Kaye M.D., Ph.D. | Chief Executive Officer and Director |
| Dr. Adrian R. Krainer Ph.D. | Co-Founder and Independent Director |
| Stephen J. Tulipano CPA, MBA | Chief Financial Officer |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Chief Medical Officer |
| Isabel Aznarez Ph.D. | Co-Founder and Group Vice President of Discovery Research |
| Dr. Huw M. Nash Ph.D. | Chief Operating Officer and Chief Business Officer |
| Eric Rojas | Head of Investor Relations |
| Jonathan Allan J.D. | Corporate Secretary and General Counsel |
| Dawn Kalmar | Chief Communications Officer |
| Joan Wood | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | ARS | Filing |
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 17, 2024 | 144 | Filing |
| Apr 11, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 1, 2024 | 144 | Filing |
| Apr 1, 2024 | 144 | Filing |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 424B5 | Filing |